Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

380
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
380
Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K
Cancer Prevention02:59

Cancer Prevention

6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVĪ”G-ZEBOV-GP-primed volunteers (Boost-EBOV).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesĀ·2026
Same author

Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers.

Frontiers in immunologyĀ·2025
Same author

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.

Frontiers in immunologyĀ·2025
Same author

DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP.

The LaryngoscopeĀ·2025
Same author

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.

Nature communicationsĀ·2025
Same author

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis.

The LaryngoscopeĀ·2023

Related Experiment Video

Updated: Jul 11, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K

Vaccines for HPV-associated diseases.

Jeffrey M Skolnik1, Matthew P Morrow1

  • 1INOVIO Pharmaceuticals, Inc., Plymouth Meeting, PA, USA.

Molecular Aspects of Medicine
|November 6, 2023
PubMed
Summary

Therapeutic vaccines offer a new way to fight human papillomavirus (HPV) infections and related cancers. DNA vaccines show promise for long-lasting immunity against persistent HPV disease.

Keywords:
Cervical cancerDNA vaccineHuman papillomavirusImmune responseSquamous intraepithelial lesionTherapeutic vaccine

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.5K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.5K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.4K

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Human papillomavirus (HPV) infection is a major global health issue, linked to various cancers.
  • Current prophylactic HPV vaccines reduce infection and cervical cancer rates but don't treat existing infections.
  • A need exists for therapeutic strategies to manage persistent HPV infections and associated conditions.

Purpose of the Study:

  • To review the development of therapeutic HPV vaccines.
  • To highlight the potential of DNA vaccines in managing HPV-related diseases.
  • To discuss the advantages and challenges of DNA vaccine platforms.

Main Methods:

  • Review of clinical data for therapeutic HPV vaccines.
  • Analysis of different vaccine platforms (peptide/protein, vector, whole-cell, nucleic acid).
  • Focus on DNA vaccine technology, including manufacturing, antigen targeting, and thermostability.

Main Results:

  • Therapeutic vaccination aims to induce cellular immunity against established HPV infections and lesions.
  • DNA vaccines elicit robust cellular and humoral immune responses, offering long-lasting immunity.
  • DNA vaccines present advantages in manufacturing, antigen targeting, repeat boosting, and thermostability.

Conclusions:

  • Therapeutic HPV vaccines, particularly DNA-based ones, represent a promising approach for managing HPV-related diseases.
  • Ongoing clinical development and delivery strategies are crucial for realizing the potential of DNA vaccines.
  • Further research is needed to overcome challenges like transfection efficiency for widespread clinical application.